CP17744631830150285 — Invega Trinz 410mg 1.32ml Dose
Cite this view
HANK Price Transparency. (n.d.). Invega Trinz 410mg 1.32ml Dose (CDM CP17744631830150285) negotiated rates. PPMan price-transparency data, derived from CMS-required hospital MRFs. Retrieved , from http://ppman.hank.ai/transparency/code/CP17744631830150285?code_type=CDM
“Invega Trinz 410mg 1.32ml Dose (CDM CP17744631830150285) negotiated rates.” HANK Price Transparency, http://ppman.hank.ai/transparency/code/CP17744631830150285?code_type=CDM. Accessed .
“Invega Trinz 410mg 1.32ml Dose (CDM CP17744631830150285) negotiated rates,” HANK Price Transparency, accessed , http://ppman.hank.ai/transparency/code/CP17744631830150285?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital machine-readable files (45 CFR 180). See methodology.
Usually $3,322–$3,738 (25th–75th percentile) across 1 hospital · 3 payers.
“Negotiated” is the hospital’s negotiated facility rate for this CDM CP17744631830150285 — the consumer-grade median across the country. It covers the facility charge only; the surgeon’s and anesthesiologist’s fees are billed separately.
Per-month price trends are temporarily unavailable while we rebuild them on quality-filtered rates. The medians, percentiles, and per-hospital rates on this page are the quality-filtered figures.
Hospital rates (per row)
Showing consumer-grade rates only. Flagged / outlier filings (excluded from the medians above) are hidden — tick “Show flagged / outlier rates” to include them.
| Hospital | Payer | Plan | Negotiated rate | Gross | Cash | Observed | Source |
|---|---|---|---|---|---|---|---|
| St Lawrence Rehabilitation Center Both | Amerihealth | HMO | $3,322.00 | $4,153.00 | $4,153.00 | 2026-03-31 | MRF ↗ |
| St Lawrence Rehabilitation Center Both | Independence Keystone Health Plan | Commercial | $3,322.00 | $4,153.00 | $4,153.00 | 2026-03-31 | MRF ↗ |
| St Lawrence Rehabilitation Center Both | Aetna | Commercial | $4,153.00 | $4,153.00 | $4,153.00 | 2026-03-31 | MRF ↗ |